Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 17/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.66 |
| ▸ | AR | P10275 | 13/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8767831 | 0.88 | PGR (0.53) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL9019768 | 0.88 | PGR (0.68) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL9019878 | 0.87 | NR3C1 (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL8767943 | 0.85 | PGR (0.51) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL8767837 | 0.85 | PGR (0.50) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL8652764 | 0.84 | PGR (0.50) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL8768109 | 0.84 | PGR (0.47) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL6453812 | 0.83 | PGR (0.65) | PGRNR3C1ARCYP3A4CYP2C8 | |
| SCHEMBL7148540 | 0.83 | PGR (0.65) | PGRNR3C1ARCYP3A4CYP2C8 | |
| SCHEMBL7148546 | 0.83 | PGR (0.65) | PGRNR3C1ARCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373832-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Context Biopharma Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023003863-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | CONTEXT BIOPHARMA INC. (US) | 2023-01-26 | — | — | WO | disclosed |